DRI Healthcare Trust (DHT-UN) investor relations material

Executive summary

• Achieved record Q2 2026 results with double-digit growth in total income, cash receipts, and adjusted EBITDA year-over-year, driven by portfolio expansion and strategic transactions.

• Monetized Ekterly investment, realizing a 1.5x return and high-20s IRR, and received FDA approval for Lumvoa (veligrotug), triggering a $75M milestone payment.

• Maintains strong liquidity and balance sheet, supporting flexibility for acquisitions and continued buybacks.

• Internalization of management and financing initiatives drove operating leverage and efficiency, eliminating performance fees.

• Renewed NCIB program and repurchased 89,513 Units in Q2 for $1.0M.

Financial highlights

• Total income reached $50.1M, up 13% year-over-year, driven by royalty income and milestone receipts.

• Adjusted EBITDA was $42.6M, up 40% year-over-year, with a margin of 92% versus 76% last year.

• Cash receipts totaled $46.5M, a 16% increase year-over-year.

• Adjusted cash earnings per unit at $0.56 for Q2 2026.

• Comprehensive earnings were $7.5M, compared to a loss of $0.7M in the prior year.

Outlook and guidance

• Confident in achieving or exceeding the high end of 2026 adjusted EBITDA guidance, with margins expected in the high 80%-90% range for the second half.

• Robust pipeline of over $3B in potential opportunities as of June 30, 2026.

• Declared a quarterly distribution of $0.11 per unit for Q3 2026, payable in October.

• Focus on long-term, sustainable growth and strong unitholder returns.

• Anticipates completing at least one transaction in the second half of 2026, with increased cadence of capital deployment.